<DOC>
	<DOC>NCT00384774</DOC>
	<brief_summary>This study evaluates the efficacy of a range of intravenous doses of COL-144 in the treatment of migraine headache in order to select a dose range for further studies.</brief_summary>
	<brief_title>A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine</brief_title>
	<detailed_description>This study is set up: - to evaluate the efficacy (headache response at two hours) of a range of intravenous doses of COL-144 in order to select a dose range for further evaluation, - to explore the time course and effect of a range of dose levels of COL-144 on features of the migraine including: headache response, proportion of patients pain-free, headache recurrence, nausea, photophobia, phonophobia, disability, use of rescue medication, patient global impression and vomiting - to explore the safety and tolerability of a range of doses of COL-144 in terms of adverse events, physical exam, vital signs, laboratory evaluations, and ECGs - to determine key PK parameters for COL-144 and to explore the relationship between the PK of COL-144 and the time course and extent of clinical response</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Patients with migraine with or without aura fulfilling the IHS diagnostic criteria 1.1 and 1.2.1 (2004) History of migraine of at least 1 year Migraine onset before the age of 50 years History of 1 8 migraine attacks per month Male or female subjects aged 18 to 65 years Female patients of childbearing potential must be using a highly effective form of contraception (eg combined oral contraceptive, IUD, abstinence, vasectomized partner) Able and willing to return to the clinic for treatment within 4 hours of the onset of a migraine headache Able and willing to give written informed consent History of life threatening or intolerable adverse reaction to any triptan Use of prescription migraine prophylactic drugs Pregnant or breastfeeding women Women of childbearing potential not using highly effective contraception History or evidence of coronary artery disease, ischemic or hemorrhagic stroke, epilepsy or any other condition placing the patient at increased risk of seizures History of hypertension (controlled or uncontrolled) Sitting BP &gt;160mmHg systolic or &gt;90mmHg diastolic on 2 repeated measurements at screening Current use of hemodynamically active cardiovascular drugs History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol Significant renal impairment Previous participation in this clinical trial Participation in any clinical trial of an experimental drug or device in the previous 30 days Any medical condition or laboratory test which in the judgment of the investigator makes the patient unsuitable for the study Relatives of, or staff directly reporting to, the investigator Patients with known hypersensitivity to COL144, other 5HT1F receptor agonists or to any excipient of COL144</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Migraine</keyword>
</DOC>